ES2758506T3 - Péptidos citotóxicos y conjugados de estos - Google Patents

Péptidos citotóxicos y conjugados de estos Download PDF

Info

Publication number: ES2758506T3
Authority: ES; Spain
Prior art keywords: methyl; methoxy; mmol; amino; pyrrolidin
Prior art date: 2013-12-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES14835606T

Other languages

English (en)

Spanish (es)

Inventor

Bernhard Geierstanger

Jan Grunewald

Weijia Ou

Tetsuo Uno

Yongqin Wan

Xing Wang

Yunho Jin

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Novartis AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-17

Filing date

2014-12-17

Publication date

2020-05-05

2014-12-17 Application filed by Novartis AG filed Critical Novartis AG

2020-05-05 Application granted granted Critical

2020-05-05 Publication of ES2758506T3 publication Critical patent/ES2758506T3/es

Status Active legal-status Critical Current

2034-12-17 Anticipated expiration legal-status Critical

Links

0 Cc(cc1)ccc1N(C)* Chemical compound Cc(cc1)ccc1N(C)* 0.000 description 21
QIAVAVZEYVSHDN-UHFFFAOYSA-N CC(C)C(C(NC(C)C(C)=O)=O)N Chemical compound CC(C)C(C(NC(C)C(C)=O)=O)N QIAVAVZEYVSHDN-UHFFFAOYSA-N 0.000 description 1
WRVNWTLHMFPJET-UHFFFAOYSA-N CC(C)C(C(NC(CCCNC(N)=O)C(C)=O)=O)N Chemical compound CC(C)C(C(NC(CCCNC(N)=O)C(C)=O)=O)N WRVNWTLHMFPJET-UHFFFAOYSA-N 0.000 description 1
NMOQMLJJSGSYFP-UHFFFAOYSA-N CCC(C(CCCCN)NC(C(Cc1ccccc1)N)=O)=O Chemical compound CCC(C(CCCCN)NC(C(Cc1ccccc1)N)=O)=O NMOQMLJJSGSYFP-UHFFFAOYSA-N 0.000 description 1
SDIDYFBTIZOPLA-UHFFFAOYSA-N CCNC(c1ccccc1)=O Chemical compound CCNC(c1ccccc1)=O SDIDYFBTIZOPLA-UHFFFAOYSA-N 0.000 description 1
JWLFIBKCSYTCKH-CSKARUKUSA-N CCO/C=[N+](\CCCCCC(O)=O)/[O-] Chemical compound CCO/C=[N+](\CCCCCC(O)=O)/[O-] JWLFIBKCSYTCKH-CSKARUKUSA-N 0.000 description 1
SESOKYDYBUBKHE-ZGSAXSQCSA-N CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccc1)C(O)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H]([C@]1(C2)CC[C@]22C1)N2C(CCCCCON)=O)=O)=O Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccc1)C(O)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H]([C@]1(C2)CC[C@]22C1)N2C(CCCCCON)=O)=O)=O SESOKYDYBUBKHE-ZGSAXSQCSA-N 0.000 description 1
CVWKPKYKUNMGSD-BYSIWNBCSA-N CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccc1)C(OC)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H]1N[C@]2(CC3)C3(C3)[C@]13C2)=O)=O Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccc1)C(OC)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H]1N[C@]2(CC3)C3(C3)[C@]13C2)=O)=O CVWKPKYKUNMGSD-BYSIWNBCSA-N 0.000 description 1
SMJMGUSLDWDDSO-SWHARQDFSA-N CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccc1)COC)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H]([C@@H]1C[C@H]2CC1)N2C(OCc(cc1)ccc1NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCCCN(C(C=C1)=O)C1=O)=O)=O)=O)=O)=O)=O Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccc1)COC)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H]([C@@H]1C[C@H]2CC1)N2C(OCc(cc1)ccc1NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCCCN(C(C=C1)=O)C1=O)=O)=O)=O)=O)=O)=O SMJMGUSLDWDDSO-SWHARQDFSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Epidemiology (AREA)
Crystallography & Structural Chemistry (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

ES14835606T 2013-12-17 2014-12-17 Péptidos citotóxicos y conjugados de estos Active ES2758506T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361917293P	2013-12-17	2013-12-17
PCT/US2014/070800 WO2015095301A2 (en)	2013-12-17	2014-12-17	Cytotoxic peptides and conjugates thereof

Publications (1)

Publication Number	Publication Date
ES2758506T3 true ES2758506T3 (es)	2020-05-05

Family

ID=52463118

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES14835606T Active ES2758506T3 (es)	2013-12-17	2014-12-17	Péptidos citotóxicos y conjugados de estos

Country Status (16)

Country	Link
US (3)	US9988420B2 (2)
EP (2)	EP3753578A1 (2)
JP (2)	JP6636925B2 (2)
KR (1)	KR20160098257A (2)
CN (1)	CN105899526A (2)
AU (1)	AU2014364812B2 (2)
BR (1)	BR112016012538A2 (2)
CA (1)	CA2930614A1 (2)
EA (1)	EA201691251A1 (2)
ES (1)	ES2758506T3 (2)
IL (1)	IL245558B (2)
MX (1)	MX2016007865A (2)
PL (1)	PL3082877T3 (2)
PT (1)	PT3082877T (2)
SG (1)	SG11201604877UA (2)
WO (1)	WO2015095301A2 (2)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2953976B1 (en) *	2013-02-08	2021-03-24	Novartis Ag	Specific sites for modifying antibodies to make immunoconjugates
HK1220626A1 (zh)	2013-03-15	2017-05-12	The Centre For Drug Research And Development	具细胞毒性和抗有丝分裂的化合物以及其使用方法
BR112016015105A8 (pt)	2013-12-27	2018-04-24	Var2 Pharmaceuticals Aps	conjugados var2csa-droga
WO2015095953A1 (en)	2013-12-27	2015-07-02	The Centre For Drug Research And Development	Sulfonamide-containing linkage systems for drug conjugates
JP2017509337A (ja) *	2014-03-12	2017-04-06	ノバルティスアーゲー	イムノコンジュゲートを作製する抗体を修飾するための特定部位
CA2951368A1 (en) *	2014-06-13	2015-12-17	Novartis Ag	Auristatin derivatives and conjugates thereof
ES2905569T3 (es)	2014-09-17	2022-04-11	Zymeworks Inc	Compuestos citotóxicos y antimitóticos y métodos para utilizarlos
US11566082B2 (en)	2014-11-17	2023-01-31	Cytiva Bioprocess R&D Ab	Mutated immunoglobulin-binding polypeptides
WO2017194593A1 (en)	2016-05-11	2017-11-16	Ge Healthcare Bioprocess R&D Ab	Method of cleaning and/or sanitizing a separation matrix
US10730908B2 (en)	2016-05-11	2020-08-04	Ge Healthcare Bioprocess R&D Ab	Separation method
WO2017194592A1 (en)	2016-05-11	2017-11-16	Ge Healthcare Bioprocess R&D Ab	Method of storing a separation matrix
US10889615B2 (en)	2016-05-11	2021-01-12	Cytiva Bioprocess R&D Ab	Mutated immunoglobulin-binding polypeptides
JP7031934B2 (ja)	2016-05-11	2022-03-08	サイティバ・バイオプロセス・アールアンドディ・アクチボラグ	分離マトリックス
US10703774B2 (en)	2016-09-30	2020-07-07	Ge Healthcare Bioprocess R&D Ab	Separation method
US10654887B2 (en)	2016-05-11	2020-05-19	Ge Healthcare Bio-Process R&D Ab	Separation matrix
US10513537B2 (en)	2016-05-11	2019-12-24	Ge Healthcare Bioprocess R&D Ab	Separation matrix
US12448411B2 (en)	2016-09-30	2025-10-21	Cytiva Bioprocess R&D Ab	Separation method
US10517958B2 (en)	2016-10-04	2019-12-31	Zymeworks Inc.	Compositions and methods for the treatment of platinum-drug resistant cancer
JOP20190187A1 (ar)	2017-02-03	2019-08-01	Novartis Ag	مترافقات عقار جسم مضاد لـ ccr7
UY38265A (es) *	2018-06-20	2020-01-31	Novartis Ag	Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
US20220017462A1 (en) *	2018-11-23	2022-01-20	WuXi Biologics Ireland Limited	Ortho-phthalaldehyde containing linkers and use for preparation of antibody-drug conjugate
KR20220151166A (ko) *	2020-03-09	2022-11-14	시그마-알드리치 컴퍼니., 엘엘씨	중간체 공통 중간체를 통한 돌라스타틴 및 아우리스타틴 유사체의 효율적인 제조
US20230181756A1 (en)	2020-04-30	2023-06-15	Novartis Ag	Ccr7 antibody drug conjugates for treating cancer
JP7670072B2 (ja) *	2021-01-18	2025-04-30	味の素株式会社	化合物またはその塩、およびそれらにより得られる抗体
WO2023061405A1 (zh) *	2021-10-12	2023-04-20	成都科岭源医药技术有限公司	一种高稳定性的靶向接头-药物偶联物
TW202412762A (zh) *	2022-07-27	2024-04-01	香港商祐方有限公司	奧瑞他汀衍生物及其結合物
WO2024152000A1 (en) *	2023-01-13	2024-07-18	The Trustees Of The University Of Pennsylvania	Disruptable linker compositions, switchable bispecific t cell nanoengager (switch-bite) compositions comprising the same, and methods of use thereof
KR20250169306A (ko)	2023-04-18	2025-12-02	아스트라제네카 아베	절단가능한 링커를 포함하는 접합체

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4458066A (en)	1980-02-29	1984-07-03	University Patents, Inc.	Process for preparing polynucleotides
WO1993003054A1 (fr)	1991-08-09	1993-02-18	Teikoku Hormone Mfg. Co., Ltd.	Nouveau derive de tetrapeptide
EP0731106B1 (en)	1993-10-01	2004-11-17	Teikoku Hormone Mfg. Co., Ltd.	Dolastatin derivatives
US5595756A (en) *	1993-12-22	1997-01-21	Inex Pharmaceuticals Corporation	Liposomal compositions for enhanced retention of bioactive agents
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
CN1113066C (zh)	1995-04-21	2003-07-02	帝国脏器制药株式会社	新型肽衍生物
EP1958962A3 (en)	1997-06-12	2013-05-01	Novartis International Pharmaceutical Ltd.	Artificial antibody polypeptides
US6153655A (en)	1998-04-17	2000-11-28	Enzon, Inc.	Terminally-branched polymeric linkers and polymeric conjugates containing the same
US7803915B2 (en)	2001-06-20	2010-09-28	Genentech, Inc.	Antibody compositions for the diagnosis and treatment of tumor
US20090068178A1 (en)	2002-05-08	2009-03-12	Genentech, Inc.	Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
JP2007524596A (ja)	2003-02-28	2007-08-30	トランスフォーム・ファーマシューティカルズ・インコーポレイテッド	共結晶医薬組成物
EP2478912B1 (en)	2003-11-06	2016-08-31	Seattle Genetics, Inc.	Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
US8288352B2 (en)	2004-11-12	2012-10-16	Seattle Genetics, Inc.	Auristatins having an aminobenzoic acid unit at the N terminus
JP2008521828A (ja)	2004-11-29	2008-06-26	シアトルジェネティックス，インコーポレイテッド	操作された抗体およびイムノコンジュゲート
DK1912677T3 (da)	2005-06-20	2014-01-13	Psma Dev Company L L C	PSMA-antistof-lægemiddel-konjugater
US7750116B1 (en)	2006-02-18	2010-07-06	Seattle Genetics, Inc.	Antibody drug conjugate metabolites
WO2007103288A2 (en)	2006-03-02	2007-09-13	Seattle Genetics, Inc.	Engineered antibody drug conjugates
AR059900A1 (es)	2006-03-17	2008-05-07	Genentech Inc	Anticuerpos anti-tat226 e inmunoconjugados
DK2211904T3 (en)	2007-10-19	2016-10-24	Seattle Genetics Inc	Cd19-binding agents and uses thereof
DK2265283T3 (da)	2008-03-18	2014-10-20	Seattle Genetics Inc	Auristatin-lægemiddel-linker-konjugater
JP5933562B2 (ja)	2010-09-29	2016-06-15	シアトルジェネティックス，インコーポレイテッド	Ｎ−カルボキシアルキル−アウリスタチンおよびその使用
EP3581206B8 (en)	2010-10-22	2025-02-19	Seagen Inc.	Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
WO2012113847A1 (en)	2011-02-25	2012-08-30	Lonza Ltd	Branched linker for protein drug conjugates
US9029406B2 (en)	2011-03-16	2015-05-12	Seattle Genetics, Inc	N-carboxyalkylauristatins and use thereof
BR112013027119A8 (pt)	2011-04-21	2018-03-06	Seattle Genetics Inc	novos conjugados ligante-droga (adcs) e uso dos mesmos
KR102356286B1 (ko)	2011-05-27	2022-02-08	암브룩스, 인코포레이티드	비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
CN104185477B (zh)	2011-11-17	2017-05-24	辉瑞公司	细胞毒性肽及其抗体‑药物缀合物
JP2015502397A (ja) *	2011-12-23	2015-01-22	ファイザー・インク	部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
EP2855520B1 (en) *	2012-06-04	2018-09-26	Novartis AG	Site-specific labeling methods and molecules produced thereby
EP2953976B1 (en) *	2013-02-08	2021-03-24	Novartis Ag	Specific sites for modifying antibodies to make immunoconjugates

2014
- 2014-12-17 JP JP2016540522A patent/JP6636925B2/ja not_active Expired - Fee Related
- 2014-12-17 EA EA201691251A patent/EA201691251A1/ru unknown
- 2014-12-17 MX MX2016007865A patent/MX2016007865A/es active IP Right Grant
- 2014-12-17 ES ES14835606T patent/ES2758506T3/es active Active
- 2014-12-17 EP EP19193628.5A patent/EP3753578A1/en not_active Withdrawn
- 2014-12-17 US US15/104,727 patent/US9988420B2/en active Active
- 2014-12-17 WO PCT/US2014/070800 patent/WO2015095301A2/en not_active Ceased
- 2014-12-17 KR KR1020167015935A patent/KR20160098257A/ko not_active Ceased
- 2014-12-17 SG SG11201604877UA patent/SG11201604877UA/en unknown
- 2014-12-17 CA CA2930614A patent/CA2930614A1/en not_active Abandoned
- 2014-12-17 BR BR112016012538A patent/BR112016012538A2/pt not_active Application Discontinuation
- 2014-12-17 EP EP14835606.6A patent/EP3082877B1/en not_active Not-in-force
- 2014-12-17 AU AU2014364812A patent/AU2014364812B2/en not_active Ceased
- 2014-12-17 PL PL14835606T patent/PL3082877T3/pl unknown
- 2014-12-17 PT PT148356066T patent/PT3082877T/pt unknown
- 2014-12-17 CN CN201480068696.XA patent/CN105899526A/zh active Pending
2016
- 2016-05-09 IL IL245558A patent/IL245558B/en not_active IP Right Cessation
2018
- 2018-04-24 US US15/961,531 patent/US10392421B2/en active Active
2019
- 2019-06-12 US US16/439,204 patent/US10787480B2/en active Active
- 2019-09-27 JP JP2019176561A patent/JP2020023514A/ja active Pending

Also Published As

Publication number	Publication date
EA201691251A1 (ru)	2016-11-30
JP2020023514A (ja)	2020-02-13
MX2016007865A (es)	2017-01-11
KR20160098257A (ko)	2016-08-18
BR112016012538A2 (pt)	2017-09-26
SG11201604877UA (en)	2016-07-28
US20180244717A1 (en)	2018-08-30
US10787480B2 (en)	2020-09-29
EP3082877B1 (en)	2019-08-28
WO2015095301A3 (en)	2015-09-03
JP6636925B2 (ja)	2020-01-29
IL245558B (en)	2020-01-30
EP3082877A2 (en)	2016-10-26
CN105899526A (zh)	2016-08-24
IL245558A0 (en)	2016-06-30
EP3753578A1 (en)	2020-12-23
US9988420B2 (en)	2018-06-05
CA2930614A1 (en)	2015-06-25
JP2017503777A (ja)	2017-02-02
US20190382441A1 (en)	2019-12-19
AU2014364812A1 (en)	2016-07-07
US10392421B2 (en)	2019-08-27
PT3082877T (pt)	2019-12-03
AU2014364812B2 (en)	2017-05-25
PL3082877T3 (pl)	2020-02-28
US20160311853A1 (en)	2016-10-27
WO2015095301A2 (en)	2015-06-25

Publication	Publication Date	Title
ES2758506T3 (es)	2020-05-05	Péptidos citotóxicos y conjugados de estos
EP3154997B9 (en)	2021-04-14	Auristatin derivatives and conjugates thereof
KR102215954B1 (ko)	2021-02-15	튜부리신 화합물, 그의 제조 및 사용 방법
ES2852052T3 (es)	2021-09-10	Péptidos citotóxicos y conjugados de fármaco anticuerpo de los mismos
KR101660146B1 (ko)	2016-09-26	에네디인 화합물, 그의 접합체, 및 그에 대한 용도 및 방법
KR20170102980A (ko)	2017-09-12	벤조디아제핀 이량체, 그의 접합체, 및 제조 및 사용 방법
KR20170102981A (ko)	2017-09-12	헤테로아릴렌-가교된 벤조디아제핀 이량체, 그의 접합체, 및 제조 및 사용 방법
JP2018528161A (ja)	2018-09-27	Ｋｓｐ阻害剤との部位特異的均一複合体
JP7023933B2 (ja)	2022-02-22	セコ－シクロプロパピロロインドール化合物、その抗体－薬物コンジュゲート、ならびに製造および使用方法
JP2026504840A (ja)	2026-02-10	リンカー、薬物リンカー、およびそれらの複合体、ならびにそれらを使用する方法
TW202024043A (zh)	2020-07-01	妥布賴森(tubulysins)及其中間體之製備之替代方法
NZ625745A (en)	2016-07-29	Fgfr antibody drug conjugates (adcs) and the use thereof